ArticleDiscover oncology2026
Comparison of efficacy and safety of definitive chemoradiotherapy for cervical cancer patients of different age groups using propensity score matching.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer (CC) ranks the fourth most common malignancies and its burden is increasingly affecting younger women. However, the correlation between age and CC prognosis is still uncertain. This retrospective study aims to analyze the efficacy and safety of definitive volumetric modulated arc therapy (VMAT) combined with adaptive brachytherapy (BT) with or without concurrent chemotherapy in CC patients of different age groups.
methodsTotally 541 CC patients diagnosed from 2014 to 2019 in our institution were enrolled and classified into 3 groups: the youth (18-44 years old), the middle-aged (45-59 years old) and the elderly ([Formula: see text] years old). Clinical outcomes including locoregional control (LC), progression-free survival (PFS), overall survival (OS) and distant metastasis-free survival (DMFS) were analyzed. Toxicities graded by the Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) including hematologic, gastrointestinal and urinary toxicities were analyzed. Comparison among three groups was conducted by [Formula: see text] test and Fisher's exact test before and after 1:1:1 ratio propensity score matching (PSM).
resultsThe median follow-up time was 65 months. Of 541 CC patients, the age-standardized 5-year rates for OS, PFS, LC and DMFS were 83.2%, 76.5%, 87.6% and 85.0% respectively. Before PSM, there was significant difference among three groups in OS (P = 0.035), but not in PFS, LC and DMFS. The 5-year OS for the youth, middle-aged and elderly group were 76.9%, 87.1% and 89.8% respectively. After PSM, there were 38 patients matched respectively in three groups, but there were no significant differences in OS, PFS, LC and DMFS. For acute toxicities, the incidences of grade 3 or 4 acute anemia of the youth, middle-aged and elderly groups after PSM were 34.2%, 13.2% and 15.8% respectively(P = 0.012). For late toxicities, the incidences of grade 3 or 4 cystitis and enterocolitis were 0.0% and 1.1%, and there was no significant difference among three groups.
conclusionDefinitive VMAT combined with 3D-IGBT with or without concurrent chemotherapy for CC treatment was effective and safe for patients of all age groups. But age is not an independent risk factor for CC prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.